IRF3 and ovarian carcinoma: We first selected 3 SLFN11-deficient (EFO-21, KURAMOCHI, RMGI, SLFN11–) and 3 SLFN11-proficient (OAW42, OV7 and OV-56, SLFN11+) ovarian cancer cell lines that were all STING pathway proficient, as illustrated by cGAS and IRF3 expression (Supplemental Figure 7A).